Syndax Pharmaceuticals, Inc. (SNDX) Total liabilities 2016–2025
Syndax Pharmaceuticals, Inc. (SNDX) total liabilities at each fiscal year-end, per SEC filings.
$465.1MFY2025 · since FY2016: $24.9M → $465.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $465.1M | +6.5% |
| FY2024 | $436.7M | +644.1% |
| FY2023 | $58.7M | +97.0% |
| FY2022 | $29.8M | -27.9% |
| FY2021 | $41.3M | -14.7% |
| FY2020 | $48.4M | +51.7% |
| FY2019 | $31.9M | +3.3% |
| FY2018 | $30.9M | -6.0% |
| FY2017 | $32.9M | +32.1% |
| FY2016 | $24.9M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice